Royalty Pharma plc (RPRX)Healthcare | Biotechnology | New York, United States | NasdaqGS
50.00 USD
+1.52
(3.135%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 50.00 Short-term: ★★★☆☆ | Long-term: ★★★★☆ | Dividends: ★★★☆☆ |
Hot Take | April 11, 2026, 3:03 p.m. EDT
RPRX is showing mixed signals. The recent price action has been volatile, with a recent dip followed by a rebound. The dividend yield is moderate, and the payout ratio is healthy, indicating sustainable dividend payments. The options activity suggests some bullish and bearish sentiment, but the overall market is balanced. Long-term investors might consider buying and holding, while short-term traders could look for momentum opportunities or consider buying calls if the price continues to rise. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.111627 |
| AutoARIMA | 0.122787 |
| AutoETS | 0.122788 |
| MSTL | 0.124003 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 3.40 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.006 |
| Excess Kurtosis | 1.22 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 2026-05-14 |
| Last Dividend Date | 2026-02-19 |
| Debt to Equity Ratio | 92.334 |
| Revenue per Share | 5.533 |
| Market Cap | 29,640,861,696 |
| Trailing P/E | 28.09 |
| Forward P/E | 9.09 |
| Beta | 0.39 |
| Profit Margins | 32.42% |
| Website | https://www.royaltypharma.com |
As of April 11, 2026, 3:03 p.m. EDT: Options activity shows a mix of call and put positioning. Calls are showing increased activity around the current price, with notable interest in strikes near the current price, indicating potential bullish sentiment. Puts are also showing some interest in lower strikes, suggesting possible bearish sentiment. However, the overall volume and open interest suggest a balanced market with both sides having some exposure.
| Last Yield | 1yr Yield | 3yr Avg | 5yr Avg |
|---|---|---|---|
| 0.52% | 2.36% | 2.79% | 2.48% |
| Date | Dividend | Yield % |
|---|---|---|
| 2026-02-20 | 0.235 | 0.520833 |
| 2025-11-14 | 0.220 | 0.564740 |
| 2025-08-15 | 0.220 | 0.611784 |
| 2025-05-16 | 0.220 | 0.657649 |
| 2025-02-21 | 0.220 | 0.673932 |
| 2024-11-15 | 0.210 | 0.842097 |
| 2024-08-16 | 0.210 | 0.803130 |
| 2024-05-16 | 0.210 | 0.788720 |
| 2024-02-15 | 0.210 | 0.737743 |
| 2023-11-16 | 0.200 | 0.801047 |
| 2023-08-17 | 0.200 | 0.731474 |
| 2023-05-18 | 0.200 | 0.640959 |
| 2023-02-15 | 0.200 | 0.575407 |
| 2022-11-17 | 0.190 | 0.489292 |
| 2022-08-18 | 0.190 | 0.471013 |
| 2022-05-19 | 0.190 | 0.525227 |
| 2022-02-17 | 0.190 | 0.529033 |
| 2021-11-18 | 0.170 | 0.449520 |
| 2021-08-19 | 0.170 | 0.487312 |
| 2021-05-19 | 0.170 | 0.475637 |
| 2021-02-18 | 0.170 | 0.411023 |
| 2020-11-19 | 0.150 | 0.407934 |
| 2020-09-14 | 0.150 | 0.426511 |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5532774 |
| Address1 | 110 East 59th Street |
| All Time High | 56.5 |
| All Time Low | 24.05 |
| Ask | 50.04 |
| Ask Size | 8 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.6 - Buy |
| Average Daily Volume10 Day | 2,642,430 |
| Average Daily Volume3 Month | 3,501,874 |
| Average Volume | 3,501,874 |
| Average Volume10Days | 2,642,430 |
| Beta | 0.388 |
| Bid | 49.94 |
| Bid Size | 3 |
| Board Risk | 4 |
| Book Value | 15.109 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 50.0 |
| Current Ratio | 2.402 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 50.0 |
| Day Low | 48.35 |
| Debt To Equity | 92.334 |
| Display Name | Royalty Pharma |
| Dividend Date | 1,773,100,800 |
| Dividend Rate | 0.94 |
| Dividend Yield | 1.88 |
| Earnings Call Timestamp End | 1,778,068,800 |
| Earnings Call Timestamp Start | 1,778,068,800 |
| Earnings Growth | 0.09 |
| Earnings Quarterly Growth | 0.029 |
| Earnings Timestamp | 1,778,070,600 |
| Earnings Timestamp End | 1,778,070,600 |
| Earnings Timestamp Start | 1,778,070,600 |
| Ebitda | 1,563,369,984 |
| Ebitda Margins | 0.65738 |
| Enterprise To Ebitda | 21.103 |
| Enterprise To Revenue | 13.873 |
| Enterprise Value | 32,991,647,744 |
| Eps Current Year | 5.09539 |
| Eps Forward | 5.49886 |
| Eps Trailing Twelve Months | 1.78 |
| Esg Populated | 0 |
| Ex Dividend Date | 1,778,803,200 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 46.3564 |
| Fifty Day Average Change | 3.6436005 |
| Fifty Day Average Change Percent | 0.07859973 |
| Fifty Two Week Change Percent | 55.327736 |
| Fifty Two Week High | 50.0 |
| Fifty Two Week High Change | 0.0 |
| Fifty Two Week High Change Percent | 0.0 |
| Fifty Two Week Low | 31.58 |
| Fifty Two Week Low Change | 18.42 |
| Fifty Two Week Low Change Percent | 0.58328056 |
| Fifty Two Week Range | 31.58 - 50.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,592,314,200,000 |
| Five Year Avg Dividend Yield | 2.28 |
| Float Shares | 392,594,248 |
| Forward Eps | 5.49886 |
| Forward P E | 9.092794 |
| Free Cashflow | -670,412,224 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 100 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 1.1244 |
| Gross Profits | 2,674,031,104 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07116 |
| Held Percent Institutions | 0.84536004 |
| Implied Shares Outstanding | 592,817,228 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-06-17 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Dividend Date | 1,771,545,600 |
| Last Dividend Value | 0.235 |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York. |
| Long Name | Royalty Pharma plc |
| Market | us_market |
| Market Cap | 29,640,861,696 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_669151476 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 770,947,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 22,218,954,350 |
| Number Of Analyst Opinions | 9 |
| Open | 48.6 |
| Operating Cashflow | 2,489,822,976 |
| Operating Margins | 0.57682997 |
| Overall Risk | 5 |
| Payout Ratio | 0.4944 |
| Peg Ratio | 2.78 |
| Phone | 212 883 0200 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 50.0 |
| Post Market Time | 1,776,468,847 |
| Previous Close | 48.48 |
| Price Eps Current Year | 9.812792 |
| Price Hint | 2 |
| Price To Book | 3.3092859 |
| Price To Sales Trailing12 Months | 12.463607 |
| Profit Margins | 0.32417 |
| Quick Ratio | 2.391 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.6 |
| Region | US |
| Regular Market Change | 1.52 |
| Regular Market Change Percent | 3.13531 |
| Regular Market Day High | 50.0 |
| Regular Market Day Low | 48.35 |
| Regular Market Day Range | 48.35 - 50.0 |
| Regular Market Open | 48.6 |
| Regular Market Previous Close | 48.48 |
| Regular Market Price | 50.0 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 3,034,650 |
| Return On Assets | 0.05151 |
| Return On Equity | 0.13204001 |
| Revenue Growth | 0.048 |
| Revenue Per Share | 5.533 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 444,379,087 |
| Shares Percent Shares Out | 0.0269 |
| Shares Short | 11,520,329 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 12,161,157 |
| Short Name | Royalty Pharma plc |
| Short Percent Of Float | 0.0273 |
| Short Ratio | 3.34 |
| Source Interval | 15 |
| State | NY |
| Symbol | RPRX |
| Target High Price | 63.0 |
| Target Low Price | 46.0 |
| Target Mean Price | 51.77778 |
| Target Median Price | 51.0 |
| Total Cash | 637,496,000 |
| Total Cash Per Share | 1.488 |
| Total Debt | 8,970,174,464 |
| Total Revenue | 2,378,192,896 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.88 |
| Trailing Annual Dividend Yield | 0.018151816 |
| Trailing Eps | 1.78 |
| Trailing P E | 28.089888 |
| Trailing Peg Ratio | 2.8668 |
| Triggerable | 1 |
| Two Hundred Day Average | 39.865 |
| Two Hundred Day Average Change | 10.134998 |
| Two Hundred Day Average Change Percent | 0.25423297 |
| Type Disp | Equity |
| Volume | 3,034,650 |
| Website | https://www.royaltypharma.com |
| Zip | 10,022 |